BoFA Notes BridgeBio Pharma, Inc. (BBIO)'s Upcoming Q4 Earnings May Have Limited Market Impact
TheFly reported on February 3 that Bank of America analyst Jason Zemansky raised its price target on BBIO to $88 from $85 and maintained a Buy rating on the shares.






